Inloggad som:
BEAMION-Lung 2
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
BEAMION-Lung 2
A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic - non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations
A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic - non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations
PLACEHOLDER
Patienter med HER2-muterad icke-småcellig lungcancer randomiseras mellan BI 1810631 jämfört med standard behandling som första linjes behandling.
(HER2 tyrosine kinase domain mutations)
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2024-08-26)